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ABSTRACT
EZH2 inhibitors have gained great interest for their use as anti-cancer therapeutics. 
However, most research has focused on EZH2 mutant cancers and recently adverse 
effects of EZH2 inactivation have come to light. To determine whether colorectal cancer 
cells respond to EZH2 inhibition and to explore which factors influence the degree of 
response, we treated a panel of 20 organoid lines derived from human colon tumors 
with different concentrations of the EZH2 inhibitor GSK126. The resulting responses 
were associated with mutation status, gene expression and responses to other drugs. 
We found that the response to GSK126 treatment greatly varied between organoid 
lines. Response associated with the mutation status of ATRX and PAX2, and correlated 
with BIK expression. It also correlated well with response to Nutlin-3a which inhibits 
MDM2-p53 interaction thereby activating p53 signaling. Sensitivity to EZH2 ablation 
depended on the presence of wild type p53, as tumor organoids became resistant 
when p53 was mutated or knocked down. Our exploratory study provides insight into 
which genetic factors predict sensitivity to EZH2 inhibition. In addition, we show that 
the response to EZH2 inhibition requires wild type p53. We conclude that a subset of 
colorectal cancer patients may benefit from EZH2-targeting therapies.
INTRODUCTION
Elevated levels of the Polycomb Group (PcG) 
protein EZH2 are found in a wide range of cancer types, 
and are often correlated with poor prognosis [1, 2]. Highly 
differentiated adult tissues generally express Ezh2 at low 
levels, while embryonic tissues and highly proliferating 
tissues have high Ezh2 expression [3–5]. Reducing cellular 
EZH2 activity has previously been shown to negatively 
affect cell proliferation of certain tumor types [6–11]. 
The advent of high-specificity small molecule inhibitors 
against EZH2 has reinvigorated the assessment of EZH2 
as a potential anti-cancer therapeutic target. Lymphomas 
with an activating mutation in the catalytic SET domain 
of EZH2 are strongly affected by treatment with the 
EZH2 inhibitor GSK126 [9] and clinical trials with EZH2 
inhibitors are currently ongoing. However, reducing 
EZH2 levels has also been shown to have its dangers, as 
particular myelodysplastic syndromes naturally inactivate 
EZH2, suggesting a tumor suppressor role for EZH2 in 
this context [12–14]. More importantly, prolonged EZH2 
depletion causes glioblastoma cells to acquire a more 
aggressive phenotype [15]. In addition, KRAS-mutant 
lung tumors seem to benefit from disruption of the 
Polycomb Repressive Complex 2 (PRC2), of which EZH2 
is a subunit [6, 16]. It is therefore crucial to thoroughly 
investigate the mutational landscape and transcriptional 
profile that define sensitivity to EZH2 inhibition. Such 
studies require a comprehensive overview of the mutations 
and gene expression patterns that define tumor types and 
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their subtypes. Colorectal cancer (CRC) is one such cancer 
that has been subject to intense molecular characterization, 
and has recently been reclassified into four consensus 
molecular subtypes (CMS) [17]. The recent advances 
in the intestinal organoid culture system have made it 
possible to in vitro propagate human CRC tumors without 
losing the genetic and expressional identity of the original 
tumor, while the diversity that is found in CRC is largely 
maintained [18, 19]. These advantages over conventional 
cell lines and mouse models, makes the organoid culture 
method an excellent tool to assess the drug response 
patterns across the different CRC subtypes. 
So far, a limited number of cancer types have 
been demonstrated to respond well to treatment with 
EZH2 inhibitors. Particularly sensitive tumors are those 
with mutated SWI/SNF [8] or containing an activating 
mutation in the SET domain of EZH2 [9]. As screening 
methods to discover cancers sensitive to EZH2 inhibition 
are principally done using conventional cancer cell lines, 
it is possible that this two-dimensional (2D) cell culture 
system does not properly represent the physiology of the 
tumor, which could impair discovery of cancers targetable 
with EZH2 inhibitors. Another possible cause for the lack 
of response by conventional cell lines could be the use of 
high-passage cell lines in such screens. 
In this exploratory study, we investigated the 
response of a panel of twenty well-characterized human 
CRC organoid lines derived from colon cancers [18] to 
treatment with the EZH2 inhibitor GSK126 over a course 
of multiple weeks. The setup of these GSK126-response 
assays (termed “viability assays” in this manuscript) 
was different from high-throughput drug screens in three 
ways. First, testing a single drug allowed us to treat larger 
numbers of organoids per dose, thus reducing noise in 
quantifying organoid viability. Second, we determined 
treatment time for each organoid line by the growth 
rate rather than having the same treatment time for all 
organoids, which allowed slowly growing organoid 
lines to develop a proper response. Third, by treating all 
organoids for at least nine days, and treating a subset of 
eight organoid lines for a prolonged period of time, long-
term effects beyond immediate response could be assessed. 
We demonstrate that this panel displays a wide 
range of sensitivity to EZH2 enzymatic inactivation. 
By performing a comprehensive analysis, we explored 
associations of GSK126 response with mutation, gene 
expression and drug response data that have previously 
been measured in these organoids [18]. We found that 
response correlates with the mutation status of a number 
of genes, including ATRX and PAX2, with expression of 
the pro-apoptotic gene BIK as well as with sensitivity 
to the MDM2 inhibitor Nutlin-3a. This study is the first 
to investigate the response of a panel of human CRC 
organoids to treatment with the epigenetic drug GSK126, 
the results of which demonstrate various degrees of 
response within the group of organoids, thereby providing 
a rationale for further investigation into its use as a therapy 
to treat CRC. In addition, we reveal a set of features that 
may predict patient response to EZH2 inhibition. 
RESULTS
EZH2 expression is increased in CRC organoids
EZH2 expression levels are often elevated in 
colorectal tumors [20]. In order to determine whether 
in vitro cultured organoids displayed a similar pattern, 
we evaluated EZH2 expression levels in the panel of 22 
CRC organoids and their normal tissue counterparts [18]. 
Normal colon-derived organoid lines had a narrow range 
of EZH2 expression as compared to CRC organoid lines, 
of which most had higher EZH2 expression levels than 
any of the normal colon-derived organoids (Figure 1A). 
Three CRC organoid lines had particularly low EZH2 
levels, two of which have originally been classified into 
the stem-like molecular subtype (which corresponds to 
CMS4 in the CMS classification [17]) and were unable 
to be propagated during the initial expansion of the panel. 
Accordingly, EZH2 expression in CMS4 samples from 
a TCGA cohort of 239 CRC samples was lower than in 
other CMS subtypes (Figure 1B). As CMS4 tumors are 
typified by a high stromal content, this lower expression 
may also be due to relative EZH2 transcript dilution 
by low EZH2-expressing stromal cells in CMS4 RNA 
samples. Unfortunately, as organoid cultures from CMS4 
tumors have a low success rate, we were unable to validate 
whether low EZH2 expression is a common feature of 
CMS4 organoids. Further, normal colon tissue expressed 
EZH2 at lower levels than CRC tissue, which is in line 
with the expression data from organoids. Taken together, 
these results show that the majority of CRC organoids have 
increased EZH2 expression, which is in concordance with 
previously published data on CRC tissue.
Large variability in growth response between 
CRC organoid lines after exposure to the EZH2 
inhibitor GSK126
In order to determine whether EZH2 is required 
for growth of CRC or one of its subtypes, we treated 
the 20 colon cancer organoid lines with the EZH2 
inhibitor GSK126. First, reduction of Histone 3 Lysine 
27 trimethylation (H3K27me3) was validated after 
14 days of GSK126 treatment for four randomly chosen 
organoid lines (Figure 1C). Next, we performed viability 
assays for all 20 organoid lines. 2000 single cells were 
seeded per well and grown for three days to form small 
organoids. They were then subjected to different GSK126 
concentrations between 1 µM and 8 µM, as previous 
studies have shown the drug’s optimal EZH2 inhibition 
activity to be within this range. After a certain number 
of days (this varied between organoid lines), one of the 
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conditions had reached growth-limiting size, which 
was typically the untreated control. At this stage, called 
passage 1, the organoids were trypsinized and single 
cells of each condition were counted. For eight organoid 
lines, we reseeded 2000 cells of each concentration 
and maintained the same treatment regimen until again 
organoids had reached growth-limiting size (between 21 
and 30 days), after which the organoids were trypsinized 
and single cells were counted (passage 2). Representative 
images of organoid lines at passage 1 and passage 2 are 
depicted in Supplementary Figure 1A and 1B, respectively. 
Viability was computed for passage 1 and passage 2 
following two different approaches, as explained in the 
Methods, using the trapezoid rule, as well as curve fitting 
(Supplementary Figure 2A and 2B). For each approach 
IC50 values and area under the curve (AUC) values 
were computed. The four resulting viability measures 
showed good correlation (Supplementary Figure 2C). We 
observed a large variability in response to GSK126 in this 
CRC organoid panel for passage 1 (Figure 1D, 1F). A few 
organoid lines were very sensitive to EZH2 inhibition, 
while others were relatively resistant. The degree of 
response was maintained for three organoid lines in 
passage 2, while four became more sensitive and only 
P18T became more resistant (Figure 1E, 1G). 
Interestingly, we noticed that some organoid lines 
grew faster when treated with low concentrations of 
GSK126, i.e. exhibiting a non-monotonous response 
Figure 1: Organoids from different CRC tumors respond differently to chemical EZH2 inhibition. (A) EZH2 expression 
in normal colonic organoids and CRC organoids. Both the mean and the variance of EZH2 expression are higher in tumor organoids as 
compared to normal organoids. (B) EZH2 expression in normal colon and the different molecular CRC subtypes. Expression data were 
taken from CRC RNA-sequencing samples from the TCGA database. CMS4 tumors express EZH2 significantly lower than other subtypes: 
comparing CMS1 and CMS4, p-value: 1.2 * 10–7, comparing CMS2 and CMS4, p-value: 1.6 * 10–7, and comparing CMS3 and CMS4, p-value: 
0.0277. EZH2 expression in normal colon tissue was lower than tumor tissue (compared with CMS1-4 combined, p-value: 2.0 * 10–15). 
The numbers below the x-axis indicate the number of samples. (C) Western blot of four organoid lines that were treated with 4 µM 
GSK126 and harvested after fourteen days. H3K27me3 is strongly reduced in GSK126-treated versus DMSO-treated samples. (D, E) 
Box plot showing the trapezoidal AUCs for all replicates of 20 CRC organoids in passage 1 (D) and eight CRC organoids in passage 2 
(E). (F, G) Box plot showing the trapezoidal IC50s for all replicates of 20 CRC organoids in passage 1 (F) and eight CRC organoids in passage 2 
(G). Horizontal gray lines within boxes demarcate the medians, boxes delineate the middle 50% of the data, and whiskers mark 25% and 
75% quartiles. The horizontal blue lines in (E and G) demarcate the medians from passage 1 for the same organoid line.
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(Supplementary Figure 2A and 2B). We grouped the 
lines into monotonous – whose viability only decreases 
with increasing GSK126 concentrations – and non-
monotonous – with a positive growth response at low 
concentrations that is at least 1.5 times of that of untreated 
control – responding organoids for both passages 
and compared molecular features for the two groups, 
as explained in the Methods. There were no strong 
differences between the two groups in the mutation data. 
Gene expression comparison between monotonous and 
non-monotonous responding organoid lines yielded four 
genes that were differentially expressed between the 
two groups. KLK6 was significantly less expressed in 
non-monotonous responders, while DMRT2, ALDH1L2 
and RAB39A expression levels were higher in this group 
(Supplementary Table 1A).
Adherent growth of two sensitive CRC organoid 
lines does not render them resistant
To investigate whether organoids would respond 
differently to EZH2 inhibition when cultured in adherent 
conditions, we transitioned two of the most sensitive 
organoid lines, P7T and P19TA, to an adherent state by 
culturing them on laminin-coated plates. These organoid-
derived adherent cell lines were then treated for 14 days 
with 4 µM of GSK126, a concentration at which both 
corresponding organoid lines were growth inhibited. 
Robust reduction of H3K27me3 was confirmed by western 
blot (Figure 2A). Strikingly, both cell lines were strongly 
inhibited by EZH2 inhibition and no resistant colonies 
grew out during the two weeks of treatment (Figure 2B). 
These results suggest that transitioning GSK126-
responsive organoids to an adherent state does not render 
them resistant to EZH2 inhibition. Of note, we were unable 
to generate adherently growing cell lines from organoid 
lines that are relatively resistant to EZH2 inhibition. 
Setup of association analysis between response to 
EZH2 inhibition and molecular features
To gain insight into the properties that might cause 
sensitivity or resistance to EZH2 inhibition, we associated 
measured molecular features of the tested organoid 
panel [18] with GSK126 response. In order to increase 
robustness of the identified associations, the same analyses 
were performed with all four computed measures of 
GSK126 response. The same analyses were performed for 
passage 1 and for passage 2. As explained in the methods 
section, we performed univariate associations (single 
features with multiple test correction) and multivariate 
associations (combinations of features).
In particular, we tested for associations between 
GSK126 response and CRC subtype status, hyper-
mutated status, mutation status and gene expression 
data. Due to the small sample size (20), many weak 
as well as cohort-specific effects were observed. This 
is especially true for passage 2, which contains only 
8 samples. We therefore focus only on the strongest 
observations that also recur in different parts of the 
analysis.
Association with subtypes and hyper-mutant 
status
No significant effects were observed in the CRC 
subtype associations using either the previously published 
subtyping by Sadanandam et al. [21] or the CMS 
subtyping [17] (Supplementary Table 1B). Four of the six 
hyper-mutants are among the most sensitive organoids 
to the EZH2 inhibitor (P7T, P24TB, P19TA and P10T), 
but the remaining two (P24TA and P19TB) are among 
the resistant samples, resulting in a weak effect with none 
of the viability measures significantly associating with 
hypermutated status (Supplementary Figure 3A).
Figure 2: Adherently cultured GSK126-responsive organoids remain sensitive to EZH2 inhibition. (A) Western blot 
confirming reduction of H3K27me3 in adherent organoid cultures upon 14 days of GSK126 treatment. (B) Left panel: microscopy images 
of  adherently cultured P7T and P19TA, treated with either 4 µM of GSK126 or DMSO for fourteen days. Right panel: bar plot showing 
the average fold expansion in number of cells after fourteen days of DMSO or GSK126 treatment. Error bars indicate standard deviation. 
Scale bar: 100 µm, same magnification applies to all images in (B).
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Response to EZH2 inhibition associates with 
ATRX and PAX2 mutation status 
We next tested for association between GSK126 
response and mutation status. Before analyzing all 
mutations reported in the panel, we looked at EZH2 and 
other PcG gene mutations. There is only one EZH2-mutant 
in the organoid panel: P10T (p.N361T missense SNP), 
which is a hyper-mutated line and among the sensitive 
organoids in both passages. This rare mutation is outside of 
the catalytic SET domain or other well-defined domains. 
Mutations that could affect other Polycomb Group genes 
were also present in one of the sensitive organoid lines: 
BMI1 bears a p.F280L missense mutation in P10T and 
P7T has an intergenic deletion 8367bp upstream of EZH1. 
Although all PcG mutations occur in sensitive organoid 
lines, each occurrence is in one sample only and cannot be 
analyzed statistically. 
For the analysis considering all mutations reported 
in the panel, we grouped collinear mutations, i.e. 
mutations present in exactly the same set of organoid 
lines. Also, a mutation was analyzed only if it is present 
in at least two samples. Finally, mutations that occur in 
hyper-mutant samples only were flagged, as they are more 
likely to be passenger mutations. Large collinear groups 
were also flagged, as there is no way to pinpoint a driver 
mutation without prior knowledge. Lastly, mutations had 
to significantly associate with response for at least two 
viability measures out of four. Using all mutations in the 
data set, we found for passage 1 the mutation status of a 
number of genes to be associating with response to EZH2 
inhibition (Supplementary Table 1C). PAX2 is among 
these genes, where mutant samples are more sensitive 
(Figure 3A). We noticed that several associating features 
had a high number of collinear mutations and many 
involved only hypermutated organoid lines. To specifically 
obtain the meaningful mutations, we reran the analysis 
using a selected list of genes that are often mutated in CRC 
[22] (Supplementary Table 1D) and found that mutant 
ATRX associated with sensitivity (Figure 3B). In fact, 
ATRX was also among the results of the first analysis that 
includes all mutations in the cohort, but it was collinear 
with seven other genes (Supplementary Table 1C). For 
passage 2, no association was found between response and 
mutation status of any gene. Multivariate analysis yielded 
only weak associations between mutation combinations 
and response (data not shown). 
GSK126 response inversely correlates with BIK 
expression 
Next, we analyzed correlations between response 
to EZH2 inhibition and gene expression, for which 
the top 2430 highly-varying genes (top 11.2%) were 
used. Notably, response does not correlate with EZH2 
expression. Again, genes whose expression significantly 
correlated with GSK126 response for multiple viability 
measures and analyses are reported here (Supplementary 
Table 1E). The best correlation for multiple viability 
measures was for BIK (Figure 3C) which encodes for 
a protein involved in apoptosis [23]. The correlation 
is inverse, i.e. organoid lines with high BIK levels are 
sensitive to GSK126 treatment. The multivariate gene 
expression associations did not yield any significant 
results. Although analysis of passage 2 yielded many 
genes whose expression highly correlated with response, 
we decided not to report these due to the low number (8) 
of tested organoid lines. 
Sensitivity to EZH2 inhibition correlates with 
activity of the p53 pathway
For 19 of the 22 CRC organoids, their responses 
to 83 drugs have been previously measured [18]. 
Besides genetic and transcriptional features, these drug 
responses can also provide insight into the mechanisms 
of response to EZH2 inhibition. We compared response 
to GSK126 with the other drug responses (Supplementary 
Figure 4A). Sensitivity to EZH2 inhibition highly 
correlated with sensitivity to Nutlin-3a (Figure 
4A, 4B), and to a lesser extent with sensitivity to 5-FU, 
PF-4708671 and Dasatinib (Figure 4A). The compound 
Nutlin-3a prevents binding of MDM2 to p53, which 
results in p53 stabilization and subsequent activation 
of downstream effector pathways [24]. Consequently, 
Nutlin-3a is most effective in cells with an intact p53 
pathway and, accordingly, in the original proof-of-
concept drug screen mutation of TP53 was associated 
with resistance to Nutlin-3a. Yet, in our own analysis 
mutation of TP53 was not significantly associated with 
resistance to GSK126. However, the p53 pathway can be 
disrupted by other means than TP53 mutation [25, 26]. 
The degree of response to Nutlin-3a, rather than TP53 
mutation, may therefore be seen as a measure for how 
intact the p53 pathway still is. To test whether sensitivity 
to EZH2 inhibition depends on an unperturbed p53 
pathway, we knocked down Ezh2 in murine tumor 
organoids with defined genotypes. These organoid lines 
were originally derived from the small intestines of 
VillinCre; Apcf/f; KRasG12D (VAR) and VillinCre; Apcf/f; 
KRasG12D; p53-/R172H (VAPR) mice. Organoids were 
subsequently transduced with Doxycycline-inducible 
constructs encoding either a short hairpin against Ezh2 or 
a control short hairpin (sh- Random) (Figure 4C). Upon 
treatment with Doxycycline, Ezh2 knockdown (KD) VAR 
organoids were growth arrested, while Ezh2-KD VAPR 
organoids showed no effect on growth (Figure 4D). 
The growth arrest in VAR was rescued by additional 
knockdown of Trp53 (Figure 4D and Supplementary 
Figure 4B). Interestingly, p53 protein levels increased 
upon Ezh2 KD in VAR as well as in the VAPR organoids 
that only have mutant p53 (Figure 4C). This suggests that 
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the detrimental effects of EZH2 inhibition are mediated 
through stabilization of p53 protein. 
DISCUSSION
The panel of human CRC organoids tested in our 
study shows a large variability in response to treatment 
with the EZH2 inhibitor GSK126, providing a rationale 
for using high-specificity EZH2 inhibitors as anti-cancer 
therapy for a subset of CRC patients. In the past years, 
several other highly specific EZH2 inhibitors have been 
characterized [8, 9, 27, 28], three of which were shown 
to cause highly similar changes in the gene expression 
profile when used on a lymphoma cell line [27], indicating 
Figure 3: Response to EZH2 inhibition associates with mutation status and BIK gene expression. (A) PAX2-mutant 
organoid lines are significantly more sensitive to GSK126 according to all four viability measures in passage 1. (B) ATRX-mutant organoid 
lines are significantly more sensitive to GSK126 for two out of four viability measures for passage 1. In A and B, four panels of box plots are 
shown (AUC: left two panels, IC50: right two panels; median: white background, fitted: gray background) comparing organoid lines that are 
wild type (left group, green dots) with organoids that are mutant (right group, red dots) for the indicated genes. Horizontal gray lines within 
boxes demarcate the medians, boxes delineate the middle 50% of the data, and whiskers mark 25% and 75% quartiles. (C) BIK expression 
inversely correlates with GSK126 response for three out of four viability measures (fitted IC50, and median and fitted AUC) in passage 1.
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a common mechanism of action both on-target and off-
target. This is not entirely surprising, as their molecular 
structures are very similar. 
With the organoid culture system becoming an 
established technique, its application in various lines of 
research, among which are small and large scale drug 
testing [18, 29–32], is being further developed. The setup 
of our viability assay made it possible to monitor the effects 
of prolonged EZH2 inhibition and allowed slowly growing 
organoids to develop a response. We did not use a fixed 
treatment time, but rather timed it by the speed of organoid 
growth. Consequently, response to EZH2 inhibition could 
be better compared between organoid lines with different 
growth rates. However, any cytotoxic effects of GSK126 
treatment impair this comparison as it aggravates the 
response of slowly growing organoid lines with a longer 
treatment time. Nevertheless, although demethylases do 
contribute to removal of H3K27me3 from the chromatin, 
cellular decline in H3K27me3 upon PRC2 ablation has 
been shown to be linked to cell division [27, 33]. 
Using four methods to compute the degree of 
response to GSK126, we identified different dynamics in 
the organoids’ responses to EZH2 inhibition. In general, 
the different viability measures highly correlated with 
one another, except for two outliers. While P8T responds 
well to the EZH2 inhibitor at high concentrations, at 
low concentrations it proliferates faster than untreated 
P8T organoids, resulting in a high AUC value, but a 
relatively low IC50 value (measured with respect to the 
original viability). P20T on the other hand shows a typical 
resistant profile, with little response at all concentrations 
and no enhanced proliferation at low concentrations, 
which resulted in a relatively lower AUC value, but high 
IC50 (Supplementary Figure 2A). Interestingly, enhanced 
growth at low GSK126 concentrations was observed for 
more organoid lines than P8T. This suggests that these 
organoids benefit from mild reduction of cellular EZH2 
activity. These observations are not entirely surprising, as 
the optimal level of EZH2 activity is context dependent. 
For instance, as opposed to its more classical role as 
Figure 4: Sensitivity to EZH2 inhibition is correlated with activity of WT-p53 signaling. (A) The four highest correlating 
drug responses with response to GSK126 (heatmap of Pearson correlations between all pairs of 84 drugs is presented in Supplementary 
Figure 4A). (B) Scatter plot showing the high correlation between the AUCs of Nutlin-3a and GSK126. (C) Western blot showing efficient 
Ezh2 KD and increased levels of Trp53 in Ezh2 KD organoids. (D) Average relative growth of VAR, VAPR and VAR-sh-Trp53 tumor 
organoids with or without Ezh2 KD, normalized to not-induced samples (”-Dox”, black bars). Error bars indicate standard deviation. 
(n = three independent experiments; 1-way ANOVA followed by Post hoc tests; *P = 6.7*10–4, only P-values < 0.05/12 are depicted).
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an oncogene, EZH2 appears to repress development 
of myelodysplastic syndrome [12, 34, 35]. In addition, 
both complete inactivation of PRC2 and overexpression 
of Ezh2 stimulate progression of KRas-dependent lung 
tumors and do so in different ways [16]. Importantly, 
this stresses the importance of optimal dosing for EZH2 
inhibition in cancer. Likewise, studies that correlated 
expression of PcG members with CRC patient prognosis 
have yielded contrasting results [20, 36–38], which 
indicates that also in CRC, PcG proteins may exert tumor 
suppressive as well as oncogenic actions depending on the 
mutational and transcriptional context. The dynamics in 
response to EZH2 inhibition that we observed will help 
us in further elucidating the conditions that define these 
actions in CRC. 
We also analyzed prolonged inhibition of EZH2 in 
eight CRC organoid lines. To our surprise, there were more 
organoids lines that became more sensitive than those 
that became more resistant after prolonged treatment. 
This may be due to the accumulating dysregulation of the 
transcriptional program, as more and more H3K27me3 
repressive marks are removed – and not replaced – from 
the chromatin over time, although the reduced viability 
might also have been caused by the dissociation to single 
cells at the start of passage 2. Alternatively, cells with 
decreased EZH2 activity may have decreased tumor-
initiating potential, resulting in a reduction of outgrowing 
organoids in passage 2. Interestingly, cellular depletion of 
the PcG protein BMI1 was demonstrated to reduce stem 
cell-properties of CRC cells [39], which may suggest that 
PcG stabilizes stemness in some CRCs. Further, we did 
not see in any of the eight organoid lines in passage 2 
a sudden growth acceleration indicative of a transition 
to a state at which cells benefit from low EZH2 levels. 
However, as this transition might require more time to 
develop or interaction with the microenvironment, adverse 
effects on patient survival because of prolonged EZH2 
inhibition [15] can still be an issue in CRC. 
Our further exploration of potential associations 
between the published organoid properties and GSK126 
response yielded a number of associating features. We 
have found that ATRX-mutant organoid lines are sensitive 
to GSK126 treatment. ATRX is frequently mutated in 
tumor cells with alternative lengthening of telomeres 
(ALT), and its loss has been shown to promote ALT 
[40– 42]. It is possible that cancer cells with ALT rely on 
PRC2 function, and that therefore inactivation of both 
ATRX and EZH2 is synthetic lethal in CRC. As EZH2 has 
previously been shown to be involved in DNA damage 
repair [43, 44], it may help cells to cope with replicative 
stress at ALT telomeres.
Mutation of PAX2 was also found to associate with 
sensitivity to EZH2 inhibition. The capacity of PAX2 to 
stimulate gene expression is lost when associated with 
GRG4 during lineage specification and leads to PRC2 
recruitment to PAX2 target genes [45]. PAX2 mutation may 
therefore cause a shift in PRC2 target genes, which would 
promote tumor progression. Sudden PRC2 inactivation by 
GSK126 treatment could then cause derepression of target 
genes, which is detrimental to cell survival or leads to cell 
differentiation. 
Further, our analysis yielded an inverse correlation 
between GSK126 response and BIK expression. It is 
conceivable that organoids with high BIK levels are more 
susceptible to apoptotic signals - for instance through p53 
signaling due to EZH2 inhibition. 
Of all the drug response associations studied, 
response to EZH2 inhibition correlated most strongly 
with response to Nutlin-3a. Nutlin-3a specifically affects 
p53-WT cells and in this panel of human CRC organoids, 
p53 mutation was previously found to associate with 
resistance to Nutlin-3a [18]. The observed responses to 
GSK126 in our study do not correlate with p53 mutation 
status, however, which is likely due to other mechanisms 
that inactivate p53 signaling. We therefore examined the 
response to EZH2 ablation in a genetically less disrupted 
background and demonstrated that the expression of 
WT p53 renders cells responsive to EZH2 inactivation. 
This response is likely triggered in combination with 
an oncogenic impulse, because normal intestinal tissue 
and small intestinal organoids are not affected by EZH2 
ablation (Koppens et al. [46] and data not shown). This 
may suggest that EZH2 suppresses oncogene-induced 
senescence in intestinal tissue by keeping p53 signaling 
in check, which could be achieved by Polycomb-mediated 
repression of CDKN2A or of target genes of p53 itself [47]. 
Here, we demonstrate how organoids derived from 
different colon tumors are affected by EZH2 inhibition 
and highlight several molecular features that associate 
with response. It will be of interest to investigate if other 
types of cancer depend on the same genetic factors in 
their response to EZH2 inhibition. The results of our 
study demonstrate the potential of EZH2 inhibitors as 
therapeutics in the treatment of CRC patients.  
MATERIALS AND METHODS
GSK126 response assays using the 3D organoid 
culture system
Organoids were gently digested to single cells 
using TrypLE Express (Life technologies) and counted. 
Cells were resuspended in Matrigel (Corning) and 
seeded onto 48-well plates with a concentration of 2000 
cells in 25 μL Matrigel per well. 250 μL of complete 
medium was then added, which consisted of basal 
medium (Advanced DMEM/F12 supplemented with 
Pen/Strep (Life technologies), Glutamax and 10 mM 
HEPES) supplemented with 1x B27 supplement (Life 
technologies), 1.25 mM N-acetyl-L-cysteine (Sigma-
Aldrich), 50 ng/mL EGF (Life technologies), 100 ng/mL 
Noggin (Peprotech), 10% Rspo1-conditioned medium, 
Oncotarget69824www.impactjournals.com/oncotarget
10 mM Nicotinamide (Sigma-Aldrich), 500 nM A-83-01 
(Tocris) and 10 µM SB202190 (Sigma-Aldrich). Three 
days after seeding, when single cells had formed small 
organoids, the medium was refreshed for medium with 
different GSK126 concentrations. Medium was refreshed 
every three days. When further growth of organoids at any 
concentration became compromised – this time differed 
between organoid lines (Supplementary Table 1F) – the 
organoids were digested to single cells with TrypLE and 
cells were counted using a Bürker counting chamber. We 
regarded conditions as being growth-compromising when 
either: the organoids had grown to such a close vicinity 
that further growth was hampered, or the culture medium 
increasingly turned acidic, or organoids started to produce 
large amounts of detached cells. For eight CRC organoid 
lines, single cells of each condition were again seeded 
at 2000 cells per well and the same GSK126 treatment 
as before passaging was continued. Selection of these 
passage 2 organoid lines was solely based on having 
a relatively medium-to-fast growth rate. All viability 
experiments were performed in triplicate or more.
GSK126 treatment of adherently cultured 
human CRC organoids
Culture plates were coated with 15 µg/mL of 
Poly-ornithine (Sigma-Aldrich) overnight at 37oC, and 
then washed three times with water. The plates were 
subsequently coated with laminin (Sigma-Aldrich) for 
at least three hours. Organoids were gently digested to 
single cells using TrypLE Express, counted and seeded on 
laminin-coated culture plates directly after laminin was 
removed. Medium was refreshed every two to three days. 
Cells were passaged by trypsinizing with TrypLE Express, 
counting, spinning down and reseeding on laminin-
coated culture plates. The medium used was complete 
medium supplemented with 10 µM Y27632 (Merck). 
Upon initiation of GSK126 treatment, 0.25 * 106 cells 
were seeded per well in a 12-well plate and treated with 
either DMSO or 4 µM of GSK126 for two weeks. Cells 
were counted at the end and during each passaging step to 
calculate the relative expansion.
Ezh2 knockdown in murine tumor organoids
293T cells were transfected with lentiviral packaging 
plasmids and pFH1t vectors containing sequences 
encoding either a short hairpin with random sequence or a 
short hairpin against Ezh2. Per construct, 4 10-cm plates 
were transfected and refreshed one day after. Two and three 
days after transfection, taps were taken, which were then 
ultracentrifuged at 20,000 rpm for 2 h. Combined pellets 
of both taps were resuspended in Advanced DMEM/
F12 supplemented with Pen/Strep (Life technologies), 
Glutamax and 10 mM HEPES) supplemented with 1x 
B27 supplement (Life technologies), 1× N2 supplement 
(Life Technologies), 1.25 mM N-acetyl-L-cysteine 
(Sigma-Aldrich), 50 ng/mL EGF (Life technologies), 
100 ng/mL Noggin (Peprotech), Polybrene (Millipore) 
and Y27632. The organoids that were subsequently 
infected with this virus were originally derived from small 
intestines of VillinCre;ApcLoxP/LoxP;KrasG12D/+ (VAR) and 
VillinCre;ApcLoxP/LoxP;KrasG12D/+;Trp53R172H/- (VAPR) mouse 
models by the lab of Owen Sansom. VAR organoids were 
also further compounded by retroviral transduction of a 
pRetrosuper-sh-p53 construct (VAR-sh-Trp53). Organoids 
were trypsinized using TrypLE (Life technologies) to 
single cells, combined with virus and centrifuged at 
600rpm and 32oC for 1 h. The cells were then incubated 
for 6 h at 37oC after which they were seeded in 
Matrigel (Corning) and overlaid with complete medium 
supplemented with Y27632. Two days after infection, 
medium was refreshed and Puromycin was added. Infected 
organoids were kept on this selection antibiotic for two 
weeks. The organoids were then treated with Doxycycline 
to induce expression of short hairpins. 
Western blotting
Western blotting was performed as described by 
Koppens et al. [46]. The following primary antibodies 
were used: anti-EZH2 (BD Biosciences), anti-H3K27me3 
(Abcam, AB64850), anti-p53 (Monosan, Monx10194) and 
anti-Vinculin (Sigma-Aldrich, V9131).
Calculating AUCs and IC50s
Viability was calculated in two different ways: using 
a piecewise linear approximation as well as continuous 
curve fitting. This resulted in four different measures 
of response: two types of area under the curve (AUC) 
and two corresponding types of IC50 (concentration 
at 50% viability). The piecewise linear AUC is simply 
the trapezoidal area under the dose response curve. The 
corresponding IC50 is interpolated from the segment 
which contains the 50% viability. In all cases, the AUC 
and IC50 were computed for each replicate independently, 
and then the median was taken over all replicate AUCs 
and replicate IC50s respectively. These are shown in 
Figure 1D–1G.
To model the peaks at the beginning of the eight-
point response curve, for some samples, we combined 
a two-parameter normal density function with a two-
parameter sigmoid function and estimated a total of 
five parameters using nonlinear least squares. These 
parameters include mean and standard deviation for the 
normal density, shift and slope for the dose response and 
a proportionality coefficient which scales the normal 
density component contribution in the fit. All replicates 
(three to four per organoid line) were taken into account 
in the estimation. For three samples (P7T, P28T in 
passage 1, P14T in passage 2) the model did not converge 
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because for these fast responders even the two-parameter 
sigmoid curve is not a good model: the two-parameter 
sigmoid is not very steep at zero concentration for most 
parametrizations. For the fit of these samples we took the 
minimum sum of squares of the residuals solution over 
500 parameter samplings. The fitted curves were used to 
obtain fitted AUCs and fitted IC50s. These are shown in 
Supplementary Figure 2A and 2B.
Processing molecular data
For this analysis, the gene expression data (for all 
22 samples) and mutation data (for all 22 samples) from 
the original publication [18] were used, and matched to 
20 samples of the 22 (two samples were not distributed 
by the original biobank). The gene expression data was 
downloaded as normalized originally (using rma-sketch, 
within Affymetrix Power Tools [18]), and row/gene mean-
centered. 
The mutation data provided by Supplementary 
Table 1J from ref. [18] was filtered to exclude mutations 
in intergenic regions, introns, silent mutations, mutations 
in non-coding regions, UTRs and flank regions. In 
addition, 12 genes, frequently mutated in and associated 
with hereditary CRC (APC, BMPR1A, MLH1, MSH2, 
MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4 
and STK11), were screened for presence of pathogenic 
germline single nucleotide variants, using the raw exome 
sequencing data [18]. This resulted in the inclusion of 
a MUTYH mutation (rs587782885) for P25T and APC 
mutations for P18T (rs62619935) and P20T (rs137854573) 
to the list of somatic mutations in Supplementary Table 1J 
from ref. [18]. Mutations were then summarized as binary 
values per gene, zero for wild type and one for mutated. 
In this analysis, no distinction was made between different 
types of mutation in the same gene.
To analyze differences between consensus 
molecular subtypes (CMS) in terms of EZH2 expression, 
we compared the expression in 239 out of 461 RNA-seq 
samples from the TCGA database (Level 3 RNA-seq data, 
frozen tissue, labelled COAD (Colon adenocarcinoma), 
from both the Illumina GA and Illumina HiSeq platforms). 
These 239 samples are such that both CMS classifiers from 
[17] assign a valid subtype and agree on the classification. 
EZH2 expression comparison between the different 
subtypes was done via a t-test.
Associating molecular features with response
For associating CRC molecular subtypes with 
response, we made use of the subtyping (developed by 
Sadanandam et al. [21]) of the panel of organoids as 
presented in the original study [18].
For both gene expression data and the mutation 
data two types of association analyses were performed. 
The first was univariate: associating single features with 
response, followed by multiple test correction. For the 
mutation data we employed t-tests of the viability of 
wild type samples versus the viability of mutant samples 
(adjusted p-value < 0.25). For gene expression, we looked 
at the correlation of expression of single genes with drug 
response (|cor| > = 0.5).
For the second arm of analysis, we looked for 
associations using all features, and due to the small sample 
size, also using a smaller selected number of features. 
For gene expression the subset was the top 11% of high-
varying genes (2430 genes with standard deviation above 
0.7). For mutations, a list of 93 selected mutations, specific 
for colon cancer was used, as derived in Iorio et al, [22].
Comparing monotonous to non-monotonous 
responders
To study the phenomenon of non-monotonicity in 
response in some of the organoids, samples were split 
into monotonic and non-monotonic (the latter being P17T, 
P19TB, and P8T in passage 1 and P18T and P31T in 
passage 2, see Supplementary Figure 2A and 2B) based 
on the criterion that there should be a viability increase 
of at least 50% for the fitted curve at the lowest nonzero 
concentration. In terms of mutations the two groups were 
tested for differences using a chi-square test for each 
mutation. To detect differences in gene expression, we 
used the standard procedure within the limma R package.
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